购物车
- 全部删除
- 您的购物车当前为空
CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers. CD24 Protein-VLP, Cynomolgus, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 3.8 kDa and the accession number is XP_015304503.1.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100 μg | ¥ 11,800 | 5日内发货 | |
500 μg | ¥ 47,500 | 5日内发货 | |
1 mg | ¥ 79,100 | 5日内发货 |
生物活性 | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
产品描述 | CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers. CD24 Protein-VLP, Cynomolgus, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 3.8 kDa and the accession number is XP_015304503.1. |
种属 | Cynomolgus |
表达系统 | HEK293 Cells |
蛋白编号 | XP_015304503.1 |
别名 | MGC75043,FLJ43543,FLJ22950,CD24A,CD24 molecule,CD 24 |
蛋白构建 | Ser26-Gly57 |
蛋白纯度 | > 90% as determined by HPLC |
分子量 | 3.8 kDa (predicted) |
内毒素 | < 1 EU/μg by the LAL method. |
缓冲液 | Supplied as 0.22 μm filtered solution in PBS (pH 7.4).Notice: If you need it for immunization, Do Not use any adjuvant. |
存储 | It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
研究背景 | CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.